Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Soligenix, Inc. (SNGX) Acquires SGX94 Drug Technology 0 comments
    Dec 18, 2012 5:24 PM | about stocks: SNGX

    Soligenix has acquired SGX94, a drug technology representing a unique approach to modulation of the innate immune system. Per the transaction, the company has also acquired all rights, including composition of matter patents, preclinical, and phase 1 clinical study datasets for SGX94.

    SGX94 is an innate defense regulator (IDR) designed to regulate the body's innate immune system to reduce inflammation, eliminate infection, and enhance tissue healing. The drug is applicable to a wide range of disease models, including life-threatening bacterial infections and severe side-effects of chemo- and/or radiation-therapy.

    SGX94 previously demonstrated safety in a phase 1 clinical study in healthy human volunteers and is the subject of an open Investigational New Drug (NYSE:IND) application, which has been cleared by the U.S. Food and Drug Administration. The drug is positioned to enter phase 2 clinical testing in humans.

    Moving forward, Soligenix said that it intends to continue development of SGX94 in cancer supportive care and infectious disease applications.

    "We are very excited by the acquisition of this cutting edge science which represents a new paradigm for the treatment of tissue injury and infection," Christopher J Schaber, PhD, president and CEO of Soligenix stated in the press release. "With SGX94 we will be able to leverage our experience in clinical development of cancer supportive care and biodefense products. We also anticipate the potential for a number of grant funding opportunities for SGX94 across both segments of our business."

    SGX94 is currently being developed pursuant to discoveries made by Professors B. Brett Finlay and Robert Hancock of the University of British Columbia, Canada; approximately $40 million have been put toward the drug's development to date.

    For more information, visit soligenix.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: SNGX
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.